Weekly, high-dose paclitaxel in advanced lung carcinoma - A phase II study with pharmacokinetics by the cancer and leukemia group B

被引:58
作者
Akerley, W
Herndon, JE
Egorin, MJ
Lyss, AP
Kindler, HL
Savarese, DM
Sherman, CA
Rosen, DM
Hollis, D
Ratain, MJ
Green, MR
机构
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84103 USA
[2] Ctr Stat, Canc & Leukemia Grp B, Durham, NC USA
[3] Univ Maryland, Dept Med, Baltimore, MD 21201 USA
[4] Missouri Bpatist Med Ctr, Dept Med, St Louis, MO USA
[5] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[6] Univ Massachusetts Mem Hlth Care, Dept Med, Worcester, MA USA
[7] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA
关键词
paclitaxel; lung carcinoma; toxicity; dose intensity; pharmacokinetics;
D O I
10.1002/cncr.11375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The Cancer and Leukemia Group B conducted a Phase II trial to evaluate the efficacy, toxicity, and pharmacokinetics of paclitaxel administered at a maximum dose density for patients with chemotherapy-naive, advanced-stage non-small cell lung carcinoma (NSCLC). METHODS. Patients with Stage IIIB/IV or recurrent NSCLC, a performance status (PS) score of 0-1, and no history of chemotherapy exposure were eligible. Paclitaxel, 150 mg/m(2), was administered over 3 hours during Weeks 1-6 of an 8-week cycle. Doses were modified for ANC < 1500/muL or for Grade 2 neuropathy on the day of therapy. Treatment continued until toxicity or disease progression. Pharmacokinetics were assessed at Weeks 1, 3, and 5 of Cycle 1. RESULTS. Thirty-eight patients (median age, 64 years; range, 31-81 years) were treated. There were 21 males (PS = 0 for 17). Eleven patients had received previous radiation, 2 had brain metastases, 25 had adenocarcinoma, 23 had Stage IV disease, 6 had StageIIIB disease, and 9 had recurrent disease. Grade 3-4 granulocytopenia occurred in 39% of patients. There were no deaths due to toxicity. Grade 2 or 3 neuropathy occurred in 29% and 24% of patients, respectively. Ten (27%) patients had Grade 3 hyperglycemia (glucose concentration > 250 mg/dL). There were 16 partial responses (42%; 95% confidence interval [CI], 26-59%). The median survival period was 12.3 months (95% CI, 7.9-19.6%), and the 1-year and 2-year survival rates were 52% (95% CI, 39-71%) and 26% (95% CI, 15-45%), respectively. Paclitaxel pharmacokinetics were consistent with published values and clearance was not induced. Older age and hyperglycemia were associated with greater neurotoxicity. CONCLUSIONS. Paclitaxel at 150 mg/m(2) per week X 6 every 8 weeks can be administered safely in the cooperative group setting. These Phase II data are comparable to those associated with combination therapy. The weekly dose-dense schedule may be more active than conventional schedules. (C) 2003 American Cancer Society.
引用
收藏
页码:2480 / 2486
页数:7
相关论文
共 18 条
[1]  
Akerley W, 1996, SEMIN ONCOL, V23, P55
[2]  
AKERLEY W, 1997, SEMIN ONCOL S12, V24
[3]  
Blagosklonny MV, 1996, CANCER RES, V56, P1851
[4]  
Bonomini M, 1997, ITAL J MINER ELECT M, V11, P9
[5]   PHASE-II STUDY OF TAXOL, MERBARONE, AND PIROXANTRONE IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - THE EASTERN COOPERATIVE ONCOLOGY GROUP RESULTS [J].
CHANG, AY ;
KIM, K ;
GLICK, J ;
ANDERSON, T ;
KARP, D ;
JOHNSON, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :388-394
[6]   PHASE-I TRIAL OF OUTPATIENT WEEKLY PACLITAXEL AND CONCURRENT RADIATION-THERAPY FOR ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
CHOY, H ;
AKERLEY, W ;
SAFRAN, H ;
CLARK, J ;
REGE, V ;
PAPA, A ;
GLANTZ, M ;
PUTHAWALA, Y ;
SODERBERG, C ;
LEONE, L .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2682-2686
[7]   EUROPEAN-CANADIAN RANDOMIZED TRIAL OF PACLITAXEL IN RELAPSED OVARIAN-CANCER - HIGH-DOSE VERSUS LOW-DOSE AND LONG VERSUS SHORT INFUSION [J].
EISENHAUER, EA ;
HUININK, WWT ;
SWENERTON, KD ;
GIANNI, L ;
MYLES, J ;
VANDERBURG, MEL ;
KERR, I ;
VERMORKEN, JB ;
BUSER, K ;
COLOMBO, N ;
BACON, M ;
SANTABARBARA, P ;
ONETTO, N ;
WINOGRAD, B ;
CANETTA, R .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2654-2666
[8]   PACLITAXEL DISPOSITION IN PLASMA AND CENTRAL NERVOUS SYSTEMS OF HUMANS AND RATS WITH BRAIN-TUMORS [J].
GLANTZ, MJ ;
CHOY, H ;
KEARNS, CM ;
MILLS, PC ;
WAHLBERG, LU ;
ZUHOWSKI, EG ;
CALABRESI, P ;
EGORIN, MJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (14) :1077-1081
[9]   STEADY-STATE PLASMA-CONCENTRATIONS AND EFFECTS OF TAXOL FOR A 250-MG/M(2) DOSE IN COMBINATION WITH GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH OVARIAN-CANCER [J].
JAMISDOW, CA ;
KLECKER, RW ;
SAROSY, G ;
REED, E ;
COLLINS, JM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 33 (01) :48-52
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481